Protalix BioTherapeutics (PLX) Raw Materials (2011 - 2026)

Protalix BioTherapeutics' Raw Materials history runs 11 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• In Q1 2026, Raw Materials rose 33.97% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (up 33.97% YoY), while the FY2025 annual figure was $6.0 million, up 31.46% from the prior year.
• Raw Materials was $6.0 million for Q1 2026 at Protalix BioTherapeutics, roughly flat from $6.0 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $6.0 million in Q1 2026 to a low of $3.1 million in Q1 2022.
• Historically, Raw Materials has averaged $4.3 million across 5 years, with a median of $4.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Raw Materials fell 10.53% in 2022, then soared 40.51% in 2023.
• A 5-year view of Raw Materials shows it stood at $3.5 million in 2022, then increased by 19.04% to $4.2 million in 2023, then advanced by 8.93% to $4.5 million in 2024, then jumped by 31.46% to $6.0 million in 2025, then gained by 0.45% to $6.0 million in 2026.
• The last three Raw Materials figures came in at $6.0 million (Q1 2026), $6.0 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.